Antibodies targeting VISTA entering the clinic are beginning to yield promising outcomes; however, more assessment and development are needed to understand the clinical consequences of different antibody Fc isotypes and to manage treatment-related adverse effects like CRS. Here, VSIR is linked to congenital rubella syndrome.